Why the study?
Does dabigatran improve clinical outcomes compared to vitamin K antagonists in real-world patients with nonvalvular atrial fibrillation?
Population
711,298 real-world patients with nonvalvular atrial fibrillation from 20 observational studies
Comparison
Dabigatran (75 mg, 110 mg, or 150 mg) vs Vitamin K antagonists (VKA)
Design
Meta-analysis
Authors
Loading...
May support dabigatran preference over VKA in real-world AF; leaves open need for randomized confirmation.
Does dabigatran improve clinical outcomes compared to vitamin K antagonists in real-world patients with nonvalvular atrial fibrillation?
In a real-world setting, dabigatran demonstrates a favorable effectiveness and safety profile compared to vitamin K antagonists in patients with nonvalvular atrial fibrillation, though with an increased risk of gastrointestinal bleeding.
Costa et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: